Results 221 to 230 of about 10,843 (242)

Real‐world evidence: Long‐term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years

American journal of hematology/oncology
Patients with sickle cell disease (SCD) and other anemias who receive blood transfusions are at risk of organ damage due to transfusional iron overload. Deferiprone is an iron chelator with a well‐established safety and efficacy profile that is indicated
J. Kwiatkowski, Alexis A. Thompson, F. Tricta, N. Temin, A. Rozova, C. Fradette, S. Badawy   +6 more
semanticscholar   +1 more source

Radiation Protection by Deferiprone in Animal Models

Hemoglobin, 2006
The effectiveness of deferiprone (L1) in removing depleted uranium (DU) and protecting animals from radiation exposure was examined. Rats that had received 2 mg/kg DU via intramuscular injection were orally administered 100, 200 or 400 mg/kg L1 for 3 days.
Kazunori Anzai, George J. Kontoghiorghes, Mizuyo Ikeda, Akira Katoh, Satoshi Fukuda, Masao Suzuki   +5 more
openaire   +3 more sources

Arthropathy in thalassaemia patients receiving deferiprone

The Lancet, 1994
The iron chelator deferiprone (L1) reduces tissue iron stores in iron-loaded patients. Three of sixteen patients treated with deferiprone developed joint pain and swelling without evidence of systemic lupus erythematosus (SLE). Articular cartilage, synovial hypertrophy and iron deposition, and synovial lining cell proliferation, with no inflammatory or
M. Berkovitch, R.M. Laxer, G. Koren, R. Inman, N.F. Olivieri, R.M. Laxer, N.F. Olivieri, K.P.H. Pritzker, M.J. Fritzler   +8 more
openaire   +5 more sources

Long-Term Therapy with Deferiprone

Acta Haematologica, 1996
Data from several trials have provided direct and supportive evidence for the efficacy of deferiprone in the treatment of iron overload in thalassemia major. Deferiprone has been shown to induce sustained decreases in body iron to concentrations associated with survival free from the complications of iron overload in deferoxamine (DFO)-treated patients.
openaire   +2 more sources

Immune and Neural Status of Thalassemic Patients Receiving Deferiprone or Combined Deferiprone and Deferoxamine Chelation Treatment

Hemoglobin, 2008
Deferiprone (L1), has previously been reported to be associated with immunological abnormalities in iron loaded thalassemia patients. However, other factors may also have similar effects such as the level of iron overload, chronic immuno-stimulation due to transfusions, splenectomy and deferoxamine (DFO).
Miranda Athanassiou-Metaxa, V Tzimouli, Dimitrios Zafiriou, Florendia Kanakoudi-Tsakalidou, Marina Economou, Vassilios Perifanis, Antonia Taparkou, Natalie Tourkantoni   +7 more
openaire   +3 more sources

Deferiprone Chelation Therapy for Thalassemia Major

Acta Haematologica, 2009
Iron overload is one of the major causes of morbidity in patients with thalassemia major. Deferiprone (DFP), an orally active iron chelator, emerged from an extensive search for new drugs to treat iron overload. Comparative studies have shown that at comparable doses the efficacy of DFP in removing body iron is similar to that of desferoxamine (DFO ...
Renzo Galanello, S. Campus
openaire   +3 more sources

Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone

Hemoglobin, 2009
Chronic iron overload from frequent blood transfusions to treat patients with severe anemias leads to significant morbidity and mortality. Although desferrioxamine, the current standard of care, is an effective iron chelator with long-term evidence, it requires tedious subcutaneous infusion that reflects negatively on patient compliance.
M.D. Cappellini, K. M. Musallam, A. T. Taher   +2 more
openaire   +3 more sources

Deferiprone for thalassaemia

The Lancet, 2000
M. J. Pippard, David J. Weatherall
openaire   +6 more sources

Deferiprone therapy for transfusional iron overload

Best Practice & Research Clinical Haematology, 2005
Iron chelation is needed to prevent damage to the heart, liver and endocrine glands from iron overload in patients with refractory anaemias who receive regular blood transfusions. Desferrioxamine is still the first-line drug, but because of its expense in many countries, and lack of compliance because of difficulty with administration, there is a major
openaire   +3 more sources

Long‐term treatment with deferiprone in a L1 veteran

European Journal of Haematology, 2005
Abstract:  We studied a patient with mild β‐thalassaemia major under treatment with the oral chelator deferiprone (DFP or L1) for about 10 yr (L1 veteran). Due to poor compliance with desferrioxamine, the patient started compassionate use of DFP at an age of 23 yr with a serum ferritin of 5200 μg/L.
MEO, Anna, RUGGERI A, LA ROSA MA, ZANGHI L, KORDES U, FISCHER R.   +5 more
openaire   +4 more sources